394 related articles for article (PubMed ID: 31152823)
1. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.
Caspa Gokulan R; Garcia-Buitrago MT; Zaika AI
Biochim Biophys Acta Rev Cancer; 2019 Aug; 1872(1):37-48. PubMed ID: 31152823
[TBL] [Abstract][Full Text] [Related]
2. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
3. Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage.
Ferrer-Torres D; Nancarrow DJ; Steinberg H; Wang Z; Kuick R; Weh KM; Mills RE; Ray D; Ray P; Lin J; Chang AC; Reddy RM; Orringer MB; Canto MI; Shaheen NJ; Kresty LA; Chak A; Wang TD; Rubenstein JH; Beer DG
Gastroenterology; 2019 Apr; 156(5):1404-1415. PubMed ID: 30578782
[TBL] [Abstract][Full Text] [Related]
4. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
[TBL] [Abstract][Full Text] [Related]
5. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Kuramochi H; Vallböhmer D; Uchida K; Schneider S; Hamoui N; Shimizu D; Chandrasoma PT; DeMeester TR; Danenberg KD; Danenberg PV; Peters JH
J Gastrointest Surg; 2004 Dec; 8(8):1007-16; discussion 1016-7. PubMed ID: 15585388
[TBL] [Abstract][Full Text] [Related]
6. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
7. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
8. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
Kaz AM; Grady WM; Stachler MD; Bass AJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.
Singhal S; Kapoor H; Subramanian S; Agrawal DK; Mittal SK
J Gastrointest Cancer; 2019 Dec; 50(4):867-878. PubMed ID: 30187205
[TBL] [Abstract][Full Text] [Related]
10. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
[TBL] [Abstract][Full Text] [Related]
11. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
12. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
13. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
Grady WM; Yu M
Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
[TBL] [Abstract][Full Text] [Related]
14. Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
Schlottmann F; Molena D; Patti MG
Updates Surg; 2018 Sep; 70(3):339-342. PubMed ID: 30039277
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for treatment of Barrett's esophagus.
Feagins LA; Souza RF
Dis Esophagus; 2005; 18(2):75-86. PubMed ID: 16053481
[TBL] [Abstract][Full Text] [Related]
17. Barrett's Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models.
Korbut E; Krukowska K; Magierowski M
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328735
[TBL] [Abstract][Full Text] [Related]
18. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.
Dighe SG; Chen J; Yan L; He Q; Gharahkhani P; Onstad L; Levine DM; Palles C; Ye W; Gammon MD; Iyer PG; Anderson LA; Liu G; Wu AH; Dai JY; Chow WH; Risch HA; Lagergren J; Shaheen NJ; Bernstein L; Corley DA; Prenen H; deCaestecker J; MacDonald D; Moayyedi P; Barr H; Love SB; Chegwidden L; Attwood S; Watson P; Harrison R; Ott K; Moebus S; Venerito M; Lang H; Mayershofer R; Knapp M; Veits L; Gerges C; Weismüller J; Gockel I; Vashist Y; Nöthen MM; Izbicki JR; Manner H; Neuhaus H; Rösch T; Böhmer AC; Hölscher AH; Anders M; Pech O; Schumacher B; Schmidt C; Schmidt T; Noder T; Lorenz D; Vieth M; May A; Hess T; Kreuser N; Becker J; Ell C; Ambrosone CB; Moysich KB; MacGregor S; Tomlinson I; Whiteman DC; Jankowski J; Schumacher J; Vaughan TL; Madeleine MM; Hardie LJ; Buas MF
Carcinogenesis; 2021 Apr; 42(3):369-377. PubMed ID: 33300568
[TBL] [Abstract][Full Text] [Related]
19. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
[TBL] [Abstract][Full Text] [Related]
20. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
